Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health Helicobacter pylori Testing Coverage …
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Helicobacter pylori Testing

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, limitations, and testing methods for diagnosing and confirming eradication of H. pylori infection for members, including adults and children, and lists situations where testing meets or does not meet criteria.

    Policy Summary
    PayerOscar Health
    PolicyHelicobacter pylori Testing
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionVerify member benefits and authorization requirements before ordering testing; document prior therapies and medication washouts when applicable.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+ & <18age-specific groups
    >=4 wkspost-treatment interval
    UBT & SATpreferred noninvasive tests
    2 wksPPI washout
    4 wksantibiotic/bismuth washout
    47evidence refs

    Coverage Criteria for H. pylori Testing

    Adult diagnostic indications (noninvasive)

    Covered when ANY of the following (adults ≥18) — noninvasive testing (UBT or stool antigen) meets criteria:

    Adult diagnostic indications: For individuals 18 years and older, urea breath testing or stool antigen testing to diagnose an H. pylori infection MEETS CRITERIA in any of the following situations: (a) dyspepsia; (b) active peptic ulcer disease; (c) past peptic ulcer disease with recurrent symptoms; (d) low-grade gastric MALT lymphoma; (e) history of resection of early gastric cancer; (f) gastric intestinal metaplasia; (g) initiating chronic or on long-term aspirin/NSAID therapy; (h) unexplained iron deficiency anemia; (i) idiopathic thrombocytopenic purpura (ITP); (j) family history of gastric cancer; (k) first-generation immigrants from a high-prevalence area.age >=18

    See Note 1 for dyspepsia definition.

    Adult invasive testing (endoscopy/alarm)

    Covered when ALL of the following (adults with endoscopy or alarm symptoms) — invasive biopsy-based testing meets criteria:

    Adult invasive testing: For individuals 18 years and older who are undergoing endoscopic examination or who have alarm symptoms, a biopsy-based endoscopic histology test AND either a rapid urease test (RUT) or a culture with susceptibility testing to diagnose an H. pylori infection MEETS CRITERIA.age >=18

    Alarm features include vomiting, GI bleeding, unexplained iron deficiency, or weight loss (see Note 2).

    Pediatric diagnostic indications (noninvasive)

    Covered when ANY of the following (children <18) — noninvasive testing meets criteria:

    Pediatric diagnostic indications (noninvasive): For individuals less than 18 years of age, urea breath testing or stool antigen testing to diagnose an H. pylori infection MEETS CRITERIA in any of the following situations: (a) gastric or duodenal ulcers or erosions; (b) family history of gastric cancer.age <18

    Pediatric invasive testing (refractory IDA)

    Covered when ALL of the following (children with refractory iron deficiency anemia) — invasive biopsy-based testing meets criteria:

    Pediatric invasive testing for refractory IDA: For individuals less than 18 years of age with refractory iron deficiency anemia, a biopsy-based endoscopic histology test AND either a rapid urease test or a culture with susceptibility testing to diagnose an H. pylori infection MEETS CRITERIA.age <18; refractory IDA

    Eradication testing

    Covered when ALL of the following — eradication testing

    Post-treatment eradication testing: For all individuals who have tested positive for H. pylori, urea breath testing or stool antigen testing to measure success of eradication MEETS CRITERIA when performed at least four weeks after completion of therapy.>=4 weeks post-treatment

    UBT is preferred for test-of-cure; monoclonal stool antigen is an alternative.

    Susceptibility testing for refractory infection

    Covered when ANY of the following — susceptibility testing

    Susceptibility testing: For individuals with a refractory H. pylori infection, susceptibility testing (culture or nucleic acid–based molecular testing) MEETS CRITERIA.refractory infection

    Can be performed on archival biopsy specimens to guide subsequent therapy selection after treatment failures.

    Not medically necessary / Not covered conditions

    Not covered in these explicit situations:

    Noninvasive testing not covered: Urea breath testing or stool antigen testing to diagnose H. pylori DOES NOT MEET CRITERIA for: (a) asymptomatic individuals of all ages; (b) adults (≥18) with typical GERD symptoms without a history of peptic ulcer disease.
    Serology not covered: Serologic (antibody) testing for H. pylori infection DOES NOT MEET CRITERIA for individuals of all ages and is not recommended for detection of active infection or for post-treatment confirmation.

    Rapid office serology tests should be avoided.

    Pediatric invasive exclusions: For individuals <18, biopsy-based histology plus RUT or culture with susceptibility DOES NOT MEET CRITERIA in: (a) children with functional abdominal pain; (b) as part of initial investigation in children with iron deficiency anemia; (c) when investigating causes of short stature.

    ESPGHAN/NASPGHAN recommendations.

    Recent medication use:

    Indications for testing (guideline-aligned indications)

    Indications to test for and treat H. pylori per major gastroenterology guidelines

    Indications: Test-and-treat or testing is indicated when any of the following are present: active or prior peptic ulcer disease; gastric MALT lymphoma; uninvestigated dyspepsia (age thresholds vary by guideline: AGA suggests testing ≤55 without alarm features; ACG suggests testing <60 without alarm features); post-endoscopic resection of early gastric cancer; unexplained iron deficiency anemia; idiopathic thrombocytopenic purpura; patients taking or initiating long-term NSAIDs or low-dose aspirin; adult household members of H. pylori–positive individuals; high‑risk populations for gastric cancer (including certain racial/ethnic groups and first‑generation immigrants from high‑prevalence areas); functional dyspepsia; and other indications noted by regional guidelines.n/a

    Age and alarm-feature thresholds differ across guidelines.

    Diagnostic methods and washout (preferred tests and pre-test considerations)

    Preferred diagnostic methods and pre-test considerations

    Testing recommendations: Prefer noninvasive testing with 13C‑urea breath test (UBT) or stool antigen test for diagnosis and for test-of-cure. Office-based serology is not recommended; lab-based serology may be used only if locally validated. Before testing, stop PPIs for at least 2 weeks and stop antibiotics/bismuth for at least 4 weeks. Re‑testing after eradication is recommended primarily for patients with peptic ulcer disease or per specific guideline indications.PPI 2 weeks; antibiotics/bismuth 4 weeks

    UBT preferred for confirmation of eradication; monoclonal stool antigen is an alternative.

    Treatment recommendations (treatment and post-treatment testing guidance)

    Treatment and post-treatment testing guidance

    Therapy selection and sequencing: Offer eradication therapy to patients who test positive. For treatment‑naive adults, optimized bismuth quadruple therapy is recommended as first‑line; alternatives (e.g., rifabutin triple therapy or PCAB+amoxicillin dual therapy) are guideline‑supported. Susceptibility‑guided therapy is recommended after two failed therapies with confirmed adherence; molecular resistance testing can be performed on archival biopsy specimens. Clarify prior macrolide exposure and local clarithromycin resistance before selecting clarithromycin‑based regimens.2 failed therapies before susceptibility testing

    Document prior therapies and adherence when considering susceptibility‑guided therapy.

    Test-of-cure: Perform post‑treatment confirmation of eradication with UBT or monoclonal stool antigen at least four weeks after completion of therapy in patients for whom test‑of‑cure is indicated (eg, peptic ulcer disease, other guideline‑specified cases). Avoid using single serological tests or rapid office serology to confirm eradication.>=4 weeks after therapy

    Pediatric criteria (pediatric-specific criteria and guidance)

    Pediatric-specific criteria and guidance

    Pediatric testing indications and methods: In children (<18), test for H. pylori when gastric or duodenal ulcers/erosions are present; do not perform noninvasive testing for initial evaluation of functional abdominal pain or as part of the initial evaluation of iron deficiency anemia. When diagnosis is pursued via endoscopy, diagnosis should be biopsy‑based with culture/molecular testing and histopathology per the Sydney system; obtain at least six gastric biopsies (3 corpus, 3 antrum). Wait 2 weeks off PPIs and 4 weeks off antibiotics/bismuth before testing or confirmation of eradication. Stool molecular tests or culture for susceptibility in children are generally not suggested for routine use.6 biopsies; PPI 2 weeks; antibiotics/bismuth 4 weeks

    Consider treatment of incidental H. pylori found at endoscopy after risk–benefit discussion with family.

    Covered when guideline-based indications and test selection are met (guideline-aligned recommendations)

    Covered when guideline-based indications and test selection are met (consensus statements and guideline citations):

    Indications from consensus/guidelines: Consensus statements (Houston, Maastricht V, ACG/AGA/ESPGHAN) recommend testing for H. pylori in patients with current or past gastric or duodenal ulcers, uninvestigated dyspepsia, MALT lymphoma, family history of gastric cancer, first‑generation immigrants from high‑prevalence areas, selected high‑risk racial/ethnic groups, and in idiopathic thrombocytopenia where indicated.
    Choice of diagnostic tests per consensus: Use tests for active infection (UBT or stool antigen) for initial diagnosis and for post‑treatment confirmation; RUT is recommended when endoscopy is indicated; serology is not recommended for detecting active infection or confirming eradication.
    Pre-test medication management per consensus: Stop PPIs 2 weeks and stop antibiotics/bismuth 4 weeks prior to testing for active infection, per Maastricht and Houston consensus recommendations.PPI 2 weeks; antibiotics/bismuth 4 weeks

    Concurrent testing with multiple modalities to diagnose H. pylori infection is not supported. Concurrent testing with any combination of the urea breath test, stool antigen testing, and/or biopsy-based testing to diagnose an H. pylori infection DOES NOT MEET CRITERIA. Providers should select a single appropriate diagnostic test for active infection based on clinical context and guideline recommendations rather than ordering overlapping tests.

    Antibody-based serologic testing is not appropriate for diagnosing active H. pylori infection. For individuals of all ages, serologic testing for H. pylori infection DOES NOT MEET CRITERIA, and consensus guidance recommends against using serology to detect active infection.

    Routine testing of asymptomatic individuals is not supported. Urea breath testing or stool antigen testing to diagnose H. pylori infection DOES NOT MEET CRITERIA for asymptomatic individuals of all ages. Pediatric guidance also recommends against screening asymptomatic children and against routine noninvasive testing for many indications such as initial evaluation of functional abdominal pain.

    Serological antibody tests and rapid office serology are not recommended for detection of active infection or for confirming eradication. Guidelines advise using tests that evaluate active infection (e.g., UBT, stool antigen, or histology when endoscopy is indicated), and recommend against single serological tests to confirm eradication.

    Noninvasive testing (UBT or stool antigen) to diagnose H. pylori infection is not appropriate for asymptomatic individuals and should only be used when guideline-based indications are met. Specifically, UBT or stool antigen testing to diagnose H. pylori infection DOES NOT MEET CRITERIA for asymptomatic individuals of all ages. For post-treatment confirmation of eradication, UBT or stool antigen testing MEETS CRITERIA when performed at least four weeks post-treatment.

    Recent use of certain medications invalidates testing. For individuals with recent use of antibiotics, proton pump inhibitors (PPIs), or bismuth, the urea breath test, stool antigen, or biopsy-based testing to diagnose an H. pylori infection DOES NOT MEET CRITERIA. Guidelines recommend stopping PPIs for at least 2 weeks and antibiotics/bismuth for at least 4 weeks before testing for active infection.

    Office-based serological tests should be avoided for routine diagnosis. NICE and pediatric guidance indicate that office-based rapid serology is not recommended for routine diagnosis and that serology should only be used if a locally validated laboratory-based test is available; otherwise, prefer UBT or stool antigen for active infection testing.

    Do not use serology to confirm eradication. Use of single serological tests to confirm eradication and use of rapid office serology for detection of active infection are not recommended. Confirm eradication with tests that detect active infection (UBT or monoclonal stool antigen) performed at least 4 weeks after completion of therapy.

    Coding and Procedure Codes

    Coding (document does not specify codes)mixed
    No CPT/ICD codes listedThis document excerpt contains guideline and clinical evidence discussion but does not list specific billing codes.
    Applicable CPT/HCPCS Procedure Codesmixed
    83009Helicobacter pylori, blood test analysis for urease activity, non-radioactive isotope (eg, C-13).
    83013Helicobacter pylori; breath test analysis for urease activity, non-radioactive isotope (eg, C-13).
    83014Helicobacter pylori; drug administration.
    86318Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single.
    87070Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and...
    87077Presumptive identification of isolates Culture, bacterial; aerobic isolate, additional methods required for definitive identification...
    87081Culture, presumptive, pathogenic organisms, screening only.
    87149Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed.
    87150Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed.
    87153Culture, typing; identification by nucleic acid sequencing method, each isolate (eg, sequencing of the 16S rRNA gene).
    1–10 of 16
    1/2
    Clarithromycin resistance threshold
    Clarithromycin resistance thresholdConsider clarithromycin-based therapy only where local clarithromycin resistance is <15%.
    When to obtain susceptibilityObtain clarithromycin susceptibility testing before using clarithromycin-based first-line therapy in regions without documented low resistance.
    Use of molecular testingMolecular resistance testing can be performed on archival biopsy specimens to guide therapy selection after treatment failure.

    Provider Actions, Authorization, and Billing Guidance

    Prior Authorization

    Verify member benefits and authorization requirements

    Coverage and authorization decisions depend on the member’s specific benefit plan and applicable medical necessity rules; providers must verify authorization requirements with the member’s benefits before ordering tests or submitting claims.

    Prior Authorization

    Order susceptibility testing for refractory infections

    Susceptibility testing (culture or nucleic-acid based) for refractory H. pylori infection meets criteria and may be used to guide therapy selection; providers should request susceptibility testing when managing refractory infection.

    Background

    H. pylori is a gram-negative, spiral bacterium associated with chronic gastritis, peptic ulcer disease, gastric adenocarcinoma and MALT lymphoma. Testing is used to detect active infection to guide eradication therapy and to confirm successful treatment; choice of test depends on age, clinical presentation, and recent medication use. Guidelines consistently recommend using tests of active infection (13C-urea breath test or stool antigen) for initial diagnosis and for post-treatment confirmation, reserving biopsy-based testing for patients undergoing endoscopy or with alarm features.

    Definitions and Test Descriptions

    UBT — urea breath test
    DefinitionUrea breath test (UBT): a noninvasive test that detects active H. pylori infection by measuring labeled CO2 after ingestion of labeled urea.
    Primary usesRecommended for initial diagnosis of active H. pylori infection and as the preferred test-of-cure after treatment.
    Guideline supportMultiple guidelines (Maastricht V, Houston Consensus, AGA) identify UBT as a preferred noninvasive diagnostic and the best option for confirmation of eradication.
    SAT — stool antigen test
    DefinitionStool antigen test (SAT): an immunoassay that detects H. pylori antigen in stool and indicates active infection.
    Primary usesUsed for initial diagnosis of active H. pylori infection and as an alternative for post-treatment confirmation (monoclonal SAT preferred).
    Policy Summary
    PayerOscar Health
    PolicyHelicobacter pylori Testing
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionVerify member benefits and authorization requirements before ordering testing; document prior therapies and medication washouts when applicable.
    SourceLink
    On This Page
    Coverage Criteria for H. pylori TestingCoding and Procedure CodesProvider Actions, Authorization, and Billing GuidanceBackgroundDefinitions and Test Descriptions
    For individuals with recent use of antibiotics, proton pump inhibitors (PPIs), or bismuth, urea breath test, stool antigen, or biopsy-based testing to diagnose H. pylori infection DOES NOT MEET CRITERIA (see washout intervals).
    Concurrent multiple tests: Concurrent testing using any combination of UBT, stool antigen testing, and/or biopsy-based testing to diagnose H. pylori infection DOES NOT MEET CRITERIA.
    Nucleic acid testing not covered: Nucleic acid testing for H. pylori DOES NOT MEET CRITERIA for situations not otherwise described as meeting criteria.
    Clarithromycin susceptibility guidance: Perform clarithromycin susceptibility testing when considering clarithromycin‑based first‑line therapy unless regional clarithromycin resistance is well documented to be <15%.clarithromycin resistance <15% to omit testing

    Maastricht V guidance.

    Billing Rule

    Use applicable CPT/HCPCS codes for authorization and claims

    Use the listed CPT/HCPCS procedure codes when requesting prior authorization or submitting claims for H. pylori testing, culture, susceptibility, and pathology services.

    • Codes include 83009, 83013, 83014, 86318, 87070, 87077, 87081, 87149, 87150, 87153, 87181, 87186, 87205, 87338, 87513, 88305.
    Prior Authorization

    No standalone prior authorization program specified in these excerpts

    No specific prior authorization program or authorization-only requirement is stated in the provided document chunks; however, coverage is still subject to member benefits and medical necessity.

    Prior Authorization

    Obtain culture or molecular susceptibility testing for refractory cases

    For refractory infection, order culture-based or nucleic-acid-based susceptibility testing (including testing from archival biopsy specimens) to identify antibiotic resistance and guide salvage therapy selection.

    • Molecular resistance testing can be performed on archival formalin-fixed paraffin-embedded gastric biopsy tissue.
    • Susceptibility testing is recommended after two failed therapies with confirmed adherence.
    Note

    Use guideline-preferred first-line regimens before salvage therapies

    Follow guideline-preferred sequencing: offer guideline-preferred first-line regimens (e.g., optimized bismuth quadruple therapy) for treatment-naive patients before alternative or salvage therapies unless susceptibility data indicate otherwise.

    • ACG 2024 recommends optimized BQT as a first-line option for treatment-naive adults.
    • If treatment-experienced, optimized BQT or other guideline-recommended salvage regimens are suggested based on prior therapies.
    Step Therapy

    Perform susceptibility-guided therapy when local resistance is not low

    Consider susceptibility-guided therapy (including clarithromycin susceptibility testing) before using clarithromycin-based first-line regimens in areas without well-documented low clarithromycin resistance; omit testing only when local resistance is <15%.

    • Maastricht V recommends clarithromycin susceptibility testing when considering standard clarithromycin-based first-line therapy except where local clarithromycin resistance is <15%.
    Step Therapy

    No step therapy rules specified in these excerpts

    There are no step therapy requirements specified in the provided document chunks; therapy selection should follow guideline recommendations and susceptibility results where applicable.

    Documentation Required

    Provide accurate documentation and note benefit-dependency

    Submit accurate clinical documentation with authorization or claims and note that application of criteria depends on the individual member’s benefit coverage at the time of request.

    • Providers are responsible for submission of accurate documentation of services performed.
    • Application of criteria is dependent upon an individual’s benefit coverage at time of request.
    Documentation Required

    Document treatment history and adherence

    Document prior H. pylori therapies, patient adherence, and prior macrolide (clarithromycin) exposure when considering susceptibility-guided therapy or clarithromycin-based regimens.

    • AGA recommends susceptibility testing after two failed therapies with confirmed adherence.
    • Clarify prior macrolide exposure before choosing clarithromycin-containing regimens.
    Documentation Required

    Document test choice and medication washout/hold

    Document the type of diagnostic test used for active infection (UBT, stool antigen, or histology when endoscopy indicated) and record medication holds: stop PPIs ≥2 weeks and antibiotics/bismuth ≥4 weeks before testing when applicable.

    • UBT and stool antigen are recommended tests for active infection and for test-of-cure.
    • Stop PPIs 2 weeks and antibiotics/bismuth 4 weeks before testing for active infection or test-of-cure.
    Note

    Publication history recorded; no extra documentation specified here

    Publication history and governance approval are recorded (06/16/2026); no additional or separate provider documentation requirements are specified in these document chunks.

    Denial Risk

    Risk of claim denial or recoupment for incorrect coding

    Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed; ensure appropriate coding per industry standards.

    • Follow coding systems including CPT, HCPCS, ICD-10, NDCs, and CMS coding guidance to avoid denials or recoupment.
    Denial Risk

    Avoid testing during invalid medication conditions (washout required)

    Testing performed without appropriate medication washout (PPIs less than 2 weeks off, or antibiotics/bismuth less than 4 weeks off) can yield inaccurate results and may be considered not meeting criteria.

    • NICE and Maastricht recommend a 2-week PPI washout and a 4-week antibiotic/bismuth washout prior to testing.
    • Testing after recent use of antibiotics, PPIs, or bismuth does not meet criteria per the policy.
    Denial Risk

    Follow government policy when conflicts exist to avoid denial

    If this policy conflicts with any applicable government policy (e.g., LCDs or NCDs), the government policy takes precedence and following the payer policy instead may lead to denial.

    Note

    No other provider actions specified in these excerpts

    No additional miscellaneous provider actions are specified in the provided document chunks.

    Guideline supportMaastricht V and pediatric societies endorse stool antigen testing as a recommended noninvasive option; monoclonal assays are preferred for test-of-cure.
    Dyspepsia
    DefinitionDyspepsia: bothersome upper abdominal symptoms often meal-related, including postprandial fullness (bloating), early satiety, or epigastric pain or burning; pain is not required for diagnosis.
    Typical featuresPredominant symptoms include fullness after meals and inability to finish a normal-sized meal due to postprandial discomfort.
    Chronic presentationWhen chronic, epigastric pain is less common than postprandial fullness or early satiety.
    Alarm features
    DefinitionAlarm features: clinical findings that warrant prompt endoscopic evaluation rather than only noninvasive testing — includes vomiting, gastrointestinal bleeding, unexplained iron deficiency, or weight loss.
    Implication for testingPresence of alarm features generally indicates need for endoscopy with biopsy rather than solely noninvasive testing for H. pylori.
    Guideline mentionACG, AGA and other guidelines list these features as triggers for endoscopic evaluation in dyspepsia.
    Pediatric patient
    DefinitionPediatric patient: children and adolescents under 18 years of age (per ESPGHAN/NASPGHAN guidance).
    Testing approachIn pediatric patients, diagnosis is recommended to be biopsy‑based when endoscopy is performed, following pediatric society guidance.
    Biopsy samplingPediatric guidance recommends obtaining at least six gastric biopsies (three from corpus and three from antrum) when endoscopy is performed.
    UBT (use for diagnosis and test-of-cure)
    DefinitionUrea breath test (UBT): noninvasive test for active H. pylori infection; recommended for initial diagnosis and for post-treatment confirmation of eradication.
    Timing for eradication testingPerform UBT at least four weeks after completion of therapy to confirm eradication.
    Preferred statusMaastricht V and Houston Consensus identify UBT as the best option for confirmation of eradication and a preferred noninvasive test for diagnosis.
    Stool antigen test (diagnostic and post-treatment use)
    DefinitionStool antigen test (HpSAg/SAT): noninvasive immunoassay detecting H. pylori antigen in stool; used for diagnosis and as an alternative for post-treatment confirmation.
    Preferred assaysMonoclonal stool antigen tests are preferred for test-of-cure; perform at least four weeks after completion of therapy.
    Pediatric notePediatric societies recommend SAT as a noninvasive diagnostic option; monoclonal SAT is an alternative to UBT for confirmation of eradication.